Press releases
- Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19
- GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19
- Moncef Slaoui Departs Galvani Bioelectronics Board of Directors
Tweets from GSK US
-
GSKUS @GSKUS
During doctor’s visits, people with #COPD may under-report or downplay the true impact of their symptoms. That’s why bringing a #caregiver to ensure open and honest communication is important. Learn more about managing the disease.
about 2 days ago -
GSKUS @GSKUS
We're proud of our partnership with @Vir_Biotech and the progress we've made in a year to study potential monoclonal antibodies to combat the #COVID19 pandemic and other viruses. Learn more about how we're combatting COVID-19: gsk.to/3fP8vMX
about 5 days ago -
GSKUS @GSKUS
Although available since 2014, only 1 in every 5 parents is aware of #meningitisB vaccination, according to a 2020 survey. #Pediatricians and family practitioners: Use these tips to help start the conversation with parents about meningococcal disease: gsk.to/3fdNs6p
about 13 days ago
